RSS-Feed abonnieren
PDF herunterladen
DOI: 10.1055/s-0042-1745768
Bone Remodeling in Mandible of Wistar Rats with Diabetes Mellitus and Osteoporosis
Funding This research was supported by Universitas Airlangga International Collaboration Research Grant with number 212/UN3/2021.
Abstract
Objectives This study aimed to determine some of bone molecular expressions and its possible bone remodeling pathway between diabetes mellitus (DM) and osteoporosis model in the mandibular bone of Wistar rats.
Materials and Methods Twenty-seven female Wistar rats were divided randomly into control and treatment groups. Treatment groups were injected with streptozotocin intraperitoneally to induce DM (P1) and underwent bilateral ovariectomy to generate osteoporosis (P2). All groups were terminated after 12 weeks. Immunohistochemical and hematoxylin–eosin staining were performed to determine the expression of Runt-related transcription factor 2 (RUNX2), Osterix, vascular endothelial growth factor (VEGF), receptor activator of nuclear factor κB ligand (RANKL), osteoprotegerin (OPG), tartrate-resistant acid phosphatase (TRAP), and observed the osteoblast and osteoclast. Statistical analysis was performed using one-way analysis of variance.
Results The lowest mean of RUNX2 and VEGF expression was found in the P2 group. The lowest mean of Osterix expression was found in the P1 group. Both P1 and P2 groups of osteoblast/osteoclast ratio were decreased. There were no significant differences in the expression of TRAP between all groups; however, increased expression of RANKL/OPG ratio was only found in the P2 group.
Conclusion DM and osteoporosis induce changes in the bone remodeling pathway which are represented by a decrease in osteoblast biomarkers and an increase in osteoclast biomarkers.
Publikationsverlauf
Artikel online veröffentlicht:
04. Juli 2022
© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Giro G, Chambrone L, Goldstein A. et al. Impact of osteoporosis in dental implants: a systematic review. World J Orthop 2015; 6 (02) 311-315
- 2 Hendrijanti N, Rostiny R, Kuntjoro M. et al. The effect of low-level estrogen in mandibular bone: an in vivo study. Dent Res J (Isfahan) 2019; 16 (02) 65-70
- 3 Meza Maurício J, Miranda TS, Almeida ML, Silva HD, Figueiredo LC, Duarte PM. An umbrella review on the effects of diabetes on implant failure and peri-implant diseases. Braz Oral Res 2019; 33 (suppl 1): e070
- 4 International Diabetes Federation. IDF Diabetes Atlas. 6th ed.. Belgium: International Diabetes Federation; 2013
- 5 Wongdee K, Charoenphandhu N. Osteoporosis in diabetes mellitus: possible cellular and molecular mechanisms. World J Diabetes 2011; 2 (03) 41-48
- 6 Chrcanovic BR, Albrektsson T, Wennerberg A. Diabetes and oral implant failure: a systematic review. J Dent Res 2014; 93 (09) 859-867
- 7 Kementerian Kesehatan RI. Waspada Diabetes Eat Well Live Well. Infodatin Pus. Data dan Inf. Kementerian Kesehatan RI. 2015
- 8 World Health Organization. Global report on diabetes. 2014; 58: 1-88
- 9 Dubey RK, Gupta DK, Singh AK. Dental implant survival in diabetic patients; review and recommendations. Natl J Maxillofac Surg 2013; 4 (02) 142-150
- 10 Dumitru N, Carsote M, Cocolos A. et al. Metabolic and bone profile in postmenopausal women with and without type 2 diabetes: a cross-sectional study. Rom J Intern Med 2019; 57 (01) 61-67
- 11 Al-Maweri SAA, Ismail NM, Ismail AR, Al-Ghashm A. Prevalence of oral mucosal lesions in patients with type 2 diabetes attending Hospital Universiti Sains Malaysia. Malays J Med Sci 2013; 20 (04) 39-46
- 12 Javed F, Romanos GE. Impact of diabetes mellitus and glycemic control on the osseointegration of dental implants: a systematic literature review. J Periodontol 2009; 80 (11) 1719-1730
- 13 Oates TW, Huynh-Ba G, Vargas A, Alexander P, Feine J. A critical review of diabetes, glycemic control, and dental implant therapy. Clin Oral Implants Res 2013; 24 (02) 117-127
- 14 Piccinin MA, Khan ZA. Pathophysiological role of enhanced bone marrow adipogenesis in diabetic complications. Adipocyte 2014; 3 (04) 263-272
- 15 Ferdous HS, Afsana F, Qureshi NK, Rouf RSB. Osteoporosis: a review. BIRDEM Med J 2016; 5 (01) 30-36
- 16 Kohli SS, Kohli VS. Role of RANKL-RANK/osteoprotegerin molecular complex in bone remodeling and its immunopathologic implications. Indian J Endocrinol Metab 2011; 15 (03) 175-181
- 17 Kementerian Kesehatan RI. Data & Kondisi Penyakit Osteoporosis di Indonesia. Infodatin Pus. Data dan Inf. Kementerian Kesehatan RI. 2015
- 18 Cochran DL. Inflammation and bone loss in periodontal disease. J Periodontol 2008; 79 (8, Suppl): 1569-1576
- 19 Li Z, Li C, Zhou Y. et al. Advanced glycation end products biphasically modulate bone resorption in osteoclast-like cells. Am J Physiol Endocrinol Metab 2016; 310 (05) E355-E366
- 20 Fowlkes JL, Bunn RC, Liu L. et al. Runt-related transcription factor 2 (RUNX2) and RUNX2-related osteogenic genes are down-regulated throughout osteogenesis in type 1 diabetes mellitus. Endocrinology 2008; 149 (04) 1697-1704
- 21 Miranda C, Giner M, Montoya MJ, Vázquez MA, Miranda MJ, Pérez-Cano R. Influence of high glucose and advanced glycation end-products (AGES) levels in human osteoblast-like cells gene expression. BMC Musculoskelet Disord 2016; 17: 377
- 22 Wallner C, Schira J, Wagner JM. et al. Application of VEGFA and FGF-9 enhances angiogenesis, osteogenesis and bone remodeling in type 2 diabetic long bone regeneration. PLoS One 2015; 10 (03) e0118823
- 23 Wu YY, Xiao E, Graves DT. Diabetes mellitus related bone metabolism and periodontal disease. Int J Oral Sci 2015; 7 (02) 63-72
- 24 Chen Y, Hu Y, Yang L. et al. Runx2 alleviates high glucose-suppressed osteogenic differentiation via PI3K/AKT/GSK3β/β-catenin pathway. Cell Biol Int 2017; 41 (08) 822-832
- 25 Rios-Arce ND, Dagenais A, Feenstra D. et al. Loss of interleukin-10 exacerbates early Type-1 diabetes-induced bone loss. J Cell Physiol 2020; 235 (03) 2350-2365
- 26 Fan J-Z, Yang L, Meng GL. et al. Estrogen improves the proliferation and differentiation of hBMSCs derived from postmenopausal osteoporosis through notch signaling pathway. Mol Cell Biochem 2014; 392 (1-2): 85-93
- 27 Raehtz S, Bierhalter H, Schoenherr D, Parameswaran N, McCabe LR. Estrogen deficiency exacerbates type 1 diabetes-induced bone TNF-α expression and osteoporosis in female mice. Endocrinology 2017; 158 (07) 2086-2101
- 28 Catalfamo DL, Britten TM, Storch DL, Calderon NL, Sorenson HL, Wallet SM. Hyperglycemia induced and intrinsic alterations in type 2 diabetes-derived osteoclast function. Oral Dis 2013; 19 (03) 303-312
- 29 Khosla S, Oursler MJ, Monroe DG. Estrogen and the skeleton. Trends Endocrinol Metab 2012; 23 (11) 576-581
- 30 Senel K, Baykal T, Seferoglu B. et al. Circulating vascular endothelial growth factor concentrations in patients with postmenopausal osteoporosis. Arch Med Sci 2013; 9 (04) 709-712
- 31 Zhang Q, Fang W, Ma L, Wang ZD, Yang YM, Lu YQ. VEGF levels in plasma in relation to metabolic control, inflammation, and microvascular complications in type-2 diabetes: a cohort study. Medicine (Baltimore) 2018; 97 (15) e0415
- 32 Hendrijantini N, Rostiny R, Kurdi A. et al. Molecular triad RANK/RANKL/OPG in mandible and femur of wistar rats (Rattus norvegicus) with type 2 diabetes mellitus. Recent Adv Biol Med. 2019; 25 (05) 11090
- 33 Hu Z, Ma C, Liang Y, Zou S, Liu X. Osteoclasts in bone regeneration under type 2 diabetes mellitus. Acta Biomater 2019; 84: 402-413
- 34 Sassi F, Buondonno I, Luppi C. et al. Type 2 diabetes affects bone cells precursors and bone turnover. BMC Endocr Disord 2018; 18 (01) 55
- 35 Li Y, Shrestha A, Zhang H. et al. Impact of diabetes mellitus simulations on bone cell behavior through in vitro models. J Bone Miner Metab 2020; 38 (05) 607-619
- 36 Xu F, Dong Y, Huang X. et al. Decreased osteoclastogenesis, osteoblastogenesis and low bone mass in a mouse model of type 2 diabetes. Mol Med Rep 2014; 10 (04) 1935-1941
- 37 Azizieh FY, Shehab D, Jarallah KA, Gupta R, Raghupathy R. Circulatory levels of RANKL, OPG, and oxidative stress markers in postmenopausal women with normal or low bone mineral density. Biomark Insights 2019; 14: 1177271919843825
- 38 Lu R, Zheng Z, Yin Y, Jiang Z. Genistein prevents bone loss in type 2 diabetic rats induced by streptozotocin. Food Nutr Res 2020; 64: 1-12
- 39 Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Väänänen HK. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 2000; 15 (07) 1337-1345
- 40 Miyazaki T, Matsunaga T, Miyazaki S, Hokari S, Komoda T. Changes in receptor activator of nuclear factor-kappaB, and its ligand, osteoprotegerin, bone-type alkaline phosphatase, and tartrate-resistant acid phosphatase in ovariectomized rats. J Cell Biochem 2004; 93 (03) 503-512
- 41 Verit FF, Yazgan P, Geyikli I, Zer Y, Çelik A. Diagnostic value of TRAP 5b activity in postmenopausal osteoporosis. J Turk Ger Gynecol Assoc 2006; 7: 120-124
- 42 Kim M, Kim HS, Kim JH. et al. Chaenomelis fructus inhibits osteoclast differentiation by suppressing NFATc1 expression and prevents ovariectomy-induced osteoporosis. BMC Complement Med Ther 2020; 20 (01) 35